Novartis AG ADR
USUSDNovartis AG ADR (MI:1NOVN) — Drug Manufacturers - General. Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 7. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.
Apie įmonę
- Svetainė
- novartis.com
- Sektorius
- Healthcare · Drug Manufacturers - General
- Būstinė
- BASEL, Switzerland
- Generalinis direktorius
- Dr. Vasant Narasimhan M.D.
- Darbuotojai
- 75 267
- Įkurta
- 1996
- Apyvartoje esančios akcijos
- 1.91 mlrd. 2025-12-31 duomenimis
- Laisvai apyvartinės akcijos
- 1.86 mlrd.
- Rinkos kapitalizacija
- 276.48 mlrd. USD
- Insaideriai
- 0.01%
- Instituciniai investuotojai
- 7.27%
- Šaka (SIC)
- Pharmaceutical Preparations
- Teisinė forma
- MVII
- ISIN
- CH0012005267
- LEI
- 5493007HIVTX6SY6XD66
- Išmokų santykis
- 56.0%
- FCF
- 17.6 mlrd. USD44%
- Skola
- 29.4 mlrd. USD1.0 m. FCF
- Dividendų stažas
- 20 m.
- Pelnas, FCF ir dividendai – už 12 mėnesių iki 31.12.2025 (naujausia įmonės ataskaita).
Aprašymas
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Biržos ir tikeriai
| Birža | Tikeris | Valiuta | Kaina | Tipas |
|---|---|---|---|---|
| US USA Stocks | NVSEF OTC | USD | 135.75 +1.14% | paprastosios akcijos |
| LSE London Stock Exchange | 0QLR IOB | CHF | 82.63 +0.00% | paprastosios akcijos |
| MI Borsa Italiana (Milan) | 1NOVN papildomas | EUR | 127.94 +1.33% | paprastosios akcijos |
| SW SIX Swiss Exchange | NOVN pagrindinis | CHF | 119.8 -0.13% | paprastosios akcijos |
| SW SIX Swiss Exchange | NOVNEE papildomas | CHF | 120.02 -1.80% | paprastosios akcijos |
| VI Vienna Stock Exchange | NOVN papildomas | EUR | 127.32 -0.31% | paprastosios akcijos |
| XETRA Xetra | NOT papildomas | EUR | 126.82 +0.48% | paprastosios akcijos |
Dividendai
Novartis AG ADR (NVSEF) dividendus moka kartą per metus. Per pastaruosius 12 mėnesių buvo sumokėta 3.7 CHF už akciją (mokėjimai: 1). Pagal išmokų istoriją kita ex-dividendų data tikėtina apie 11.03.2027. Nepertraukiamų dividendų metai: 20.
| Ex data | Išmoka | Suma | % | Tipas | Tikeris |
|---|---|---|---|---|---|
| 2026-03-11 | 2026-03-12 | 3.7000 CHF | 3.3/3.3 % | metinis | US:NVSEF |
| 2025-03-12 | 2025-03-13 | 3.5000 CHF | 3.1/3.1 % | metinis | US:NVSEF |
Šios savaitės naujienos
Naujienų iš įmonės svetainės kol kas nėra.
Didžiausi akcininkai
| Turėtojas | Dalis | Akcijos | Ataskaitos data |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.35% | 27.43 mln. | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.9% | 18.24 mln. | 2026-06-30 |
| Fisher Asset Management,… | 0.76% | 15.52 mln. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.67% | 13.69 mln. | 2026-08-31 |
| Goldman Sachs TRT II-Gol… | 0.6% | 12.19 mln. | 2026-07-31 |
| Artisan Partners Funds I… | 0.51% | 10.29 mln. | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 0.44% | 8.9 mln. | 2026-06-30 |
| Morgan Stanley | 0.43% | 8.73 mln. | 2026-06-30 |
| Dimensional Fund Advisor… | 0.4% | 8.12 mln. | 2026-06-30 |
| Fidelity Concord Street… | 0.35% | 7.12 mln. | 2026-07-31 |
| Primecap Management Comp… | 0.32% | 6.59 mln. | 2026-06-30 |
| iShares Trust-iShares MS… | 0.32% | 6.53 mln. | 2026-08-31 |
| LOOMIS SAYLES & CO L P | 0.26% | 5.24 mln. | 2026-06-30 |
| MFS Series Trust XVII-MF… | 0.26% | 5.22 mln. | 2026-06-30 |
| Bank of America Corporat… | 0.24% | 4.91 mln. | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 0.23% | 4.66 mln. | 2026-07-31 |
| VANGUARD CHESTER FUNDS-V… | 0.21% | 4.25 mln. | 2026-06-30 |
| Franklin Resources, Inc. | 0.16% | 3.25 mln. | 2026-06-30 |
| Blackrock Inc. | 0.15% | 3.05 mln. | 2026-06-30 |
| Goldman Sachs Group Inc | 0.15% | 2.98 mln. | 2026-06-30 |
| Northern Trust Corporati… | 0.14% | 2.79 mln. | 2026-06-30 |
| DFA INVESTMENT DIMENSION… | 0.11% | 2.14 mln. | 2026-04-30 |
| LOOMIS SAYLES FUNDS II-L… | 0.07% | 1.42 mln. | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 0.06% | 1.21 mln. | 2026-06-30 |
| Franklin Mutual Series F… | 0.06% | 1.19 mln. | 2026-06-30 |
| JANUS INVESTMENT FUND-Ja… | 0.05% | 949 726 | 2026-06-30 |
| Principal Funds, Inc-Equ… | 0.05% | 945 091 | 2026-04-30 |
| Dimensional ETF Trust-Di… | 0.04% | 888 855 | 2026-04-30 |
| Franklin Mutual Series F… | 0.04% | 812 618 | 2026-06-30 |
| Dimensional ETF Trust-Di… | 0.04% | 716 836 | 2026-04-30 |
| Pacer Advisors, Inc. | 0.02% | 482 153 | 2026-06-30 |
| Partners Capital Investm… | 0% | 24 335 | 2026-06-30 |
| Paradigm Asset Managemen… | 0% | 21 514 | 2026-06-30 |
| Generali Investments Cee… | 0% | 15 729 | 2026-06-30 |
